Claudia Busonero
Imperial College London
CancerReceptorEstrogen receptor alphaEpidermal growth factorTamoxifenCarfilzomibFulvestrantThioridazineMitoxantroneCancer researchBreast cancerCell growthSignal transductionMedicineIntracellularCell cultureEstrogen receptorTranscription factorBiologyCell biology
15Publications
8H-index
152Citations
Publications 13
Newest
#1Claudia BusoneroH-Index: 8
#2Stefano LeoneH-Index: 21
Last. Filippo AcconciaH-Index: 30
view all 9 authors...
Estrogen receptor α expressing breast cancers (BC) are classically treated with endocrine therapy. Prolonged endocrine therapy often results in a metastatic disease (MBC), for which a standardized effective therapy is still lacking. Thus, new drugs are required for primary and metastatic BC treatment. Here, we report that the Food and Drug Administration (FDA)-approved drugs, ouabain and digoxin, induce ERα degradation and prevent proliferation in cells modeling primary and metastatic BC. Ouabai...
3 CitationsSource
Kinetic analyses of diverse physiological processes have the potential to unveil new aspects of the molecular regulation of cell biology at temporal levels. 17beta-estradiol (E2) regulates diverse physiological effects by binding to the estrogen receptor alpha (ERalpha), which primarily works as a transcription factor. Although many molecular details of the modulation of ERalpha transcriptional activity have been discovered including the impact of receptor plasma membrane localization and its re...
6 CitationsSource
#1Manuela CipollettiH-Index: 8
#2Stefano LeoneH-Index: 21
Last. Filippo AcconciaH-Index: 30
view all 5 authors...
Kinetic analyses of diverse physiological processes have the potential to unveil new aspects of the molecular regulation of cell biology at temporal levels. 17beta-estradiol (E2) regulates diverse physiological effects by binding to the estrogen receptor alpha (ERalpha), which primarily works as a transcription factor. Although many molecular details of the modulation of ERalpha transcriptional activity have been discovered including the impact of receptor plasma membrane localization and its re...
Source
Abstract With the advent of omic technologies, our understanding of the molecular mechanisms underlying estrogen receptor α (ERα)-expressing breast cancer (BC) progression has grown exponentially. Nevertheless, the most widely used therapy for inhibiting this disease is endocrine therapy (ET) (i.e., aromatase inhibitors, tamoxifen - Tam, faslodex/fulvestrant - FUL). However, in a considerable number of cases, prolonged patient treatment with ET generates the development of resistant tumor cells ...
15 CitationsSource
#1Claudia BusoneroH-Index: 8
#2Stefano LeoneH-Index: 21
Last. Filippo AcconciaH-Index: 30
view all 4 authors...
Purpose Most breast cancers (BCs) express estrogen receptor α (ERα) and are treated with the endocrine therapy (ET) drugs 4OH-tamoxifen (Tam) and fulvestrant (ICI 182,780; ICI). Unfortunately, a high fraction of ET treated women relapses and becomes resistant to ET. Therefore, additional anti-BC drugs are needed. Recently, we proposed that the identification of novel anti-BC drugs can be achieved using modulation of the intracellular ERα content in BC cells as a pharmacological target. Here, we ...
7 CitationsSource
#1Claudia BusoneroH-Index: 8
#2Stefano LeoneH-Index: 21
Last. Filippo AcconciaH-Index: 30
view all 4 authors...
Purpose: Most breast cancers (BCs) express estrogen receptor α (ERα) and are treated with the endocrine therapy (ET) drugs 4OH-tamoxifen (Tam) and fulvestrant (i.e., ICI182,780-ICI). Unfortunately, a high fraction of ET-treated women relapses and become resistant to ET. Therefore, additional anti-BC drugs are needed. Recently, we proposed that the identification of novel anti-BC drugs can be achieved using the modulation of the ERα intracellular content in BC cells as a pharmacological target. H...
1 CitationsSource
#1Stefano LeoneH-Index: 21
#2Claudia BusoneroH-Index: 8
Last. Filippo AcconciaH-Index: 30
view all 3 authors...
17β-estradiol (E2) regulates diverse physiological effects including cell proliferation through the estrogen receptor α (ERα), which as a transcription factor drives gene transcription and as an extra-nuclear localized receptor triggers the membrane-dependent activation of diverse kinase cascades. E2 also modifies ERα intracellular levels via diverse intracellular mechanisms. In this way, the E2-acivated ERα integrates signaling cascades with the modulation of receptor intracellular concentratio...
10 CitationsSource
Abstract Most cases of breast cancer (BC) are estrogen receptor α-positive (ERα+) at diagnosis. The presence of ERα drives the therapeutic approach for this disease, which often consists of endocrine therapy (ET). 4OH-Tamoxifen and faslodex (i.e., fulvestrant - ICI182,780) are two ETs that render tumor cells insensitive to 17β-estradiol (E2)-dependent proliferative stimuli and prevent BC progression. However, ET has limitations and serious failures in different tissues and organs. Thus, there is...
9 CitationsSource
#1Claudia BusoneroH-Index: 8
#2Stefano LeoneH-Index: 21
Last. Filippo AcconciaH-Index: 30
view all 3 authors...
14 CitationsSource
#1Hetal Patel (Imperial College London)H-Index: 16
#2Rezvan AbduljabbarH-Index: 6
Last. Simak Ali (Imperial College London)H-Index: 49
view all 23 authors...
Purpose: CDK-activation kinase (CAK) is required for the regulation of the cell-cycle and is a trimeric complex consisting of Cyclin Dependent Kinase 7 (CDK7), Cyclin H and the accessory protein, MAT1. CDK7 also plays a critical role in regulating transcription, primarily by phosphorylating RNA polymerase II, as well as transcription factors such as estrogen receptor-alpha(ERalpha).). Deregulation of cell cycle and transcriptional control is aare general featurefeatures of cancertumor cells, hig...
38 CitationsSource
12
Close Researchers